louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07014670: Validity and Reliability of the Postural Habits and Awareness Scale
Official title: Validity and Reliability of the Postural Habits and Awareness Scale in Patients Diagnosed With Fibromyalgia in Turkey
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Fibromyalgia
Keywords: reability
validity
Postural Habit and Awareness Scale
Lead sponsor: Bitlis Eren University
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Fibromyalgia

Brief summary: The aim of this study was to examine the validity and reliability of the Turkish version of the Postural Habits and Awareness Scale in Fibromyalgia patients.

Detailed description: Postural Habit and Awareness Scale is a scale developed for healthy individuals. For this reason, when applying to any disease group, other parameters belonging to that disease group should also be evaluated. For this purpose, Fibromyalgia Impact Questionnaire, Body Perception Scale, Body Awareness Questionnaire, Visual Analog Scale and Short Form-12 questionnaires were also used in the study. Fibromyalgia is a disease that affects the whole body and generally causes pain and stiffness complaints. For this reason, the whole body should be evaluated. Fibromyalgia Impact Questionnaire was used to define and indicate the level of fibromyalgia effects of the patients. For validity and reliability analyses, Body Perception Scale and Body Awareness Questionnaire questionnaires were used to compare the Postural Habit and Awareness scale. At the same time, Short Form-12 questionnaire was used to examine the patients' pain severity and the effects of the disease on daily life.

Eligibility criteria: Inclusion Criteria:

* Those who have been diagnosed with Fibromyalgia according to the American Rheumatology Association criteria and have been over for at least 6 months,
* Those who do not have a history of any psychiatric disease,
* Those who have the ability to lie down, sit and stand without any assistance.

Exclusion Criteria:

* Pregnant individuals,
* Those who have pain complaints due to another disease (rheumatic, heart or infectious diseases),
* Those who make changes in physical activity and lifestyle during work,
* Those with any neurological disease

Primary outcomes:
measure: Postural Habit and Awareness Scale
timeFrame: 7-10 days
Secondary outcomes:
measure: Fibromyalgia Impact Questionnaire
timeFrame: 2 days
measure: Body Perception Scale
timeFrame: 2 days
measure: Body Awareness Questionnaire
timeFrame: 2 days
measure: Visual Analog Scale
timeFrame: 2 days
measure: Short Form-12
timeFrame: 2 days
Other outcomes:
Locations:
city: Bitlis
country: Turkey
facility: Bitlis Eren University
state: Merkez
Study officials:
References:
Clinical trial NCT04006470: Meta-analysis of Stannous Fluoride and the Effects on Enamel Erosion
Official title: Bioavailable Stannous Fluoride Dentifrice Meta-Analyses: Effects on Dentine Hypersensitivity and Enamel Erosion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Enamel Erosion
Lead sponsor: Procter and Gamble
Sponsor class: INDUSTRY
First posted: 2019-07-05
Enrollment: 172
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This meta-analysis includes healthy adult male and females.

Brief summary: The aim of this 5 study analysis was to compare the effect of bioavailable stannous fluoride (SnF2) dentifrices to assess enamel erosion protection in-situ using surface profilometry.


Eligibility criteria: Inclusion Criteria:

* healthy subjects

Primary outcomes:
measure: Change from Baseline Surface profilometry
timeFrame: 10 days
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Multiple P&G Investigation Clinical Sites
state: Ohio
Study officials:
References:
Clinical trial NCT06267170: A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
Official title: A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: SCLC,Extensive Stage
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2024-02-20
Enrollment: 288
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with extensive stage small cell lung cancer treated with adebrelimab

Brief summary: This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy


Eligibility criteria: Inclusion Criteria:

1. Sign informed consent and join the study voluntarily;
2. Patients diagnosed with extensive small cell lung cancer;
3. Age ≥18 years old;
4. Have at least one measurable lesion (according to RECIST 1.1);
5. The investigators judged that adebrelimab treatment was acceptable;
6. Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;

Exclusion Criteria:

1. Allergic to adebrelimab and its excipients;
2. Patients who have also received other immune drugs or therapies;
3. Patients who are participating in other interventional studies;
4. patients with other malignant tumors;
5. Pregnant or lactating women;
6. The investigator considers that the patient is not suitable to participate in any other conditions of the study.

Primary outcomes:
measure: Safety (Occurrence of ≥ Grade 3 AE)
timeFrame: End of each cycle (each cycle is 28 days)
Secondary outcomes:
measure: PFS
timeFrame: End of every two cycles (each cycle is 28 days)
measure: ORR
timeFrame: End of every two cycles (each cycle is 28 days)
measure: OS
timeFrame: End of every two cycles (each cycle is 28 days)
measure: DCR
timeFrame: End of every two cycles (each cycle is 28 days)
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03203070: Laparoscopic-guided TAP Block in Patients Undergoing Gastric Bypass
Official title: Laparoscopic-guided Transversus Abdominis Plane (TAP) Block for Postoperative Pain Control in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Pain, Postoperative
Lead sponsor: Hospital General Universitario Elche
Sponsor class: OTHER
First posted: 2017-06-29
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A prospective randomized trial will be performed. Patients undergoing gastric bypass will be randomized into 2 groups: patients undergoing laparoscopic-guided transversus abdominis plane (TAP) block as part of multimodal analgesia (Group 1), associated with postoperative intravenous analgesia, and patients receiving only postoperative intravenous analgesia (Group 2).

Postoperative pain will be assessed with a Visual Analogic Scale 24h after surgery and morphine needs will be quantified.

Detailed description: A prospective randomized trial will be performed. Patients undergoing laparoscopic Roux-en-Y gastric bypass will be randomized into 2 groups: patients undergoing laparoscopic-guided TAP block with 30 ml Bupivacaine 0.5%, as part of multimodal analgesia (Group 1), associated with postoperative intravenous analgesia (Metamizol 2g/8h and Acetaminophen 1g/8h), and patients receiving only postoperative intravenous analgesia (Metamizol 2g/8h and Acetaminophen 1g/8h) (Group 2).

Postoperative pain will be assessed with a Visual Analogic Scale 24 hours after surgery and morphine needs will be quantified.

Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) \>40 Kg/m2
* BMI \>35 Kg/m2 and obesity associated comorbidities
* Patients undergoing laparoscopic Roux en Y gastric bypass

Exclusion Criteria:

* Patients undergoing other bariatric procedures, different than Roux en Y gastric bypass
* Patients undergoing open bariatric surgery

Primary outcomes:
measure: Postoperative pain
timeFrame: 24 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Elche
country: Spain
facility: General Hospital Elche
state: Alicante
Study officials:
affiliation: Hospital Universitario Rey Juan Carlos
name: Manule Duran
role: STUDY_DIRECTOR
References:
citation: Ruiz-Tovar J, Garcia A, Ferrigni C, Gonzalez J, Levano-Linares C, Jimenez-Fuertes M, Llavero C, Duran M. Laparoscopic-Guided Transversus Abdominis Plane (TAP) Block as Part of Multimodal Analgesia in Laparoscopic Roux-en-Y Gastric Bypass Within an Enhanced Recovery After Surgery (ERAS) Program: a Prospective Randomized Clinical Trial. Obes Surg. 2018 Nov;28(11):3374-3379. doi: 10.1007/s11695-018-3376-8.
Clinical trial NCT02051270: Cognitive Impairment and Balance in Elderly
Official title: Mild Cognitive Impairment and Balance in Elderly
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mild Cognitive Impairment
Keywords: Elderly
Nursing homes
Mild cognitive impairment
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2014-01-31
Enrollment: 82
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elders

Brief summary: One important issue in older adults with cognitive problems is the higher risk of fall due to decreased motor function and balance. The objective of this study is to evaluate the repercussions of mild cognitive impairment in balance in elderly.

Detailed description: Mild cognitive impairment is described as a transitional stage between normal ageing and dementia, and reflects the clinical situation where a person has memory complaints and objective evidence of cognitive impairment but no evidence of dementia. Mild cognitive is important in older people and it is also important to evaluate its repercussion in balance.

Eligibility criteria: Inclusion Criteria:

* Nursing home residents.

Exclusion Criteria:

* Surgery on lower limbs.
* Traumatic damage on lower limbs.
* Severe cognitive impairment in order not to complete the assessment.

Primary outcomes:
measure: Dynamic balance
timeFrame: baseline
Secondary outcomes:
measure: Cognitive impairment
timeFrame: baseline
measure: Attention
timeFrame: baseline
measure: Cognitive flexibility
timeFrame: baseline
Other outcomes:
Locations:
city: Granada
country: Spain
facility: Faculty of health Sciences. University of Granada
Study officials:
affiliation: Universidad de Granada
name: Marie Carmen Valenza, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Diaz-Pelegrina A, Cabrera-Martos I, Lopez-Torres I, Rodriguez-Torres J, Valenza MC. [Effects of cognitive state on balance disturbances and gait disorders in institutionalised elderly]. Rev Esp Geriatr Gerontol. 2016 Mar-Apr;51(2):88-91. doi: 10.1016/j.regg.2015.07.014. Epub 2015 Nov 2. Spanish.
Clinical trial NCT00492570: GER-009-06-AVX Early Therapy in Multiple Sclerosis
Official title: GER-009-06-AVX Early Therapy in Multiple Sclerosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Relapsing-Remitting Multiple Sclerosis
Keywords: Multiple Sclerosis
Cognitive Dysfunction in Multiple sclerosis
early treatment
Avonex
interferon beta 1a
Cognitive Dysfunction
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2007-06-27
Enrollment: 230
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: multi-center using 150-200 neurologists and their patient populations.

Brief summary: This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.

Detailed description: This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.

Eligibility criteria: Inclusion Criteria:

* CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis

Exclusion Criteria:

* treatment with DMT during the last 12 months

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Biogen
name: Biogen-Idec Study Director
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03981770: Characterisation of Gut Microbiota, Bispectral Index Data and Plasma Kynurenine in Patients Undergoing Thyroid Surgery
Official title: Characterisation of Gut Microbiota, Bispectral Index Data and Plasma Kynurenine in Patients Undergoing Thyroid Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Deprivation
Lead sponsor: China Medical University, China
Sponsor class: OTHER
First posted: 2019-06-11
Enrollment: 33
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study is a case-controlled observational trial. Forty patients will be divided into 2 groups (good or poor sleepers) depending on their first postoperative night Bispectral index data. Firstly, this study aims to characterise the lung microbiota in patients treated with thyroid surgery. Secondly, it aims to evaluate microbiota and its influence on plasma kynurenine.

Brief summary: The study is a case-controlled observational trial. Forty patients will be divided into 2 groups (good or poor sleepers) depending on their first postoperative night Bispectral index data. Firstly, this study aims to characterise the lung microbiota in patients treated with thyroid surgery. Secondly, it aims to evaluate microbiota and its influence on plasma kynurenine.

Detailed description: The study is a case-controlled observational trial. Forty patients will be divided into 2 groups (good or poor sleepers) depending on their first postoperative night Bispectral index data. Firstly, this study aims to characterise the lung microbiota in patients treated with thyroid surgery. Secondly, it aims to evaluate microbiota and its influence on plasma kynurenine.

Eligibility criteria: Inclusion Criteria:

* ethnic Chinese;
* age, 18 to 65 years old;
* American Society of Anaesthesiologists (ASA) physical status I or II

Exclusion Criteria:

* Cognitive difficulties
* Affiliated with the Social Security System
* Partial or complete gastrectomy
* Previous esophageal surgery
* Inability to conform to the study's requirements
* Deprivation of a right to decide by an administrative or juridical entity
* Ongoing participation or participation in another study \<1 month ago

Primary outcomes:
measure: gut microbiota
timeFrame: the first postoperative night
Secondary outcomes:
measure: Bispectral index data
timeFrame: the first postoperative night
measure: plasma kynurenine concentrations
timeFrame: baseline and the first postoperative night
Other outcomes:
Locations:
city: Shenyang
country: China
facility: the First Hospital of China Medical University
state: Liaoning
Study officials:
References:
Clinical trial NCT01678170: Clinical Application of Breast Blood-oxygen Functional Imaging Technology
Official title: Clinical Application of Breast Blood-oxygen Functional Imaging Technology
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Diseases
Keywords: blood-oxygen functional imaging technology
diagnosis
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
First posted: 2012-09-03
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female with breast lump, received breast ultrasound and mammography

Brief summary: This trial is going to evaluate the value of blood-oxygen functional imaging technology in the diagnosis of breast diseases.


Eligibility criteria: Inclusion Criteria:

* female older than 18 years breast lump received breast ultrasound and mammography

Exclusion Criteria:

* After core-needle biopsy or resection After neoadjuvant chemotherapy, radiotherapy or endocrine therapy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Department of Breast Imaging, Tianjin Medical University Cancer Hospital
state: Tianjin
Study officials:
affiliation: Department of Breast Imaging, Tianjin Medical University Cancer Hospital
name: Peifang Liu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00898170: Effect of Myoma Removal on Blood Pressure and Erythropoetin Level
Official title: Effect of Myoma Removal on Blood Pressure and Erythropoetin Level
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myoma
Hypertension
Keywords: myoma
hypertension
erythropoetin
blood pressure
erythropoetin level
Lead sponsor: Shiraz University of Medical Sciences
Sponsor class: OTHER
First posted: 2009-05-12
Enrollment: 28
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The effect of myoma removal was studied on 28 patients with hypertension and myoma by holter monitoring and erythropoetin level check.

Detailed description: Background:

Myoma is the most common gynecoid tumor and produces many vasoactive substances, which may be a cause for secondary hypertension. Early reports suggested the association of myoma and hypertension. We studied the effect of myoma removal on hypertension and erythropoietin level to evaluate this hypothesis.

Patients \& Methods:

In this single centered prospective cohort study, in twenty eight patients who were candidates for myomectomy due to myoma, 24 hour holter monitoring of blood pressure and serum erythropoietin were checked before and 6 weeks after hysterectomy.

Eligibility criteria: Inclusion Criteria:

* candidate for myoma removal by hysterectomy
* operable
* hysterectomy is indicated

Exclusion Criteria:

* patient refusal
* inoperable patients
* other secondary cases of hypertension

Primary outcomes:
measure: 24 hour holter monitoring of blood pressure
timeFrame: 6 weeks
Secondary outcomes:
measure: erythropoetin level
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Shiraz
country: Iran, Islamic Republic of
facility: Cardiology Ward Shiraz University of Medical Sciences
state: Fars
Study officials:
affiliation: Shiraz University of Medical Sciences
name: javad kojuri, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04308070: Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
Official title: Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Benign Prostatic Hyperplasia
Keywords: Image-guided
BPH
Aquablation
AQUABEAM
LUTS
Tissue resection
Robotics
Lead sponsor: PROCEPT BioRobotics
Sponsor class: INDUSTRY
First posted: 2020-03-13
Enrollment: 26
Sex: MALE
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A dual-arm prospective, interventional clinical trial to evaluate the safety and performance of obtaining hemostasis with catheters along with the use or absence of a hemostatic agent following treatment with the AQUABEAM System.

Detailed description: PROCEPT BioRobotics has developed the AQUABEAM, a personalized image-guided waterjet resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue in males suffering from LUTS due to BPH. The primary objective of this study is to evaluate the safety and performance of obtaining hemostasis using balloon catheters with and without hemostatic agents following prostate resection using AQUABEAM for the treatment of LUTS resulting from BPH. Up to 50 participants will be included in the trial at one clinical study site. All patients will be followed up for 3 months for safety assessment prior to study exit. The trial is a dual-arm prospective, interventional clinical trial.

Eligibility criteria: Inclusion Criteria:

* Male
* BPH symptoms

Exclusion Criteria:

* Serious concurrent medical conditions

Primary outcomes:
measure: Number of subjects that do not require a transfusion and do not return to the operating room for hematuria management within 7 days following the index procedure.
timeFrame: 7 days post-op
Secondary outcomes:
Other outcomes:
Locations:
city: Nadiad
country: India
facility: Muljibhai Patel Urological Hospital
state: Gujarat
Study officials:
References:
Clinical trial NCT02307370: Atherectomy By Laser Ablation With Turbo-Elite
Official title: Atherectomy By Laser Ablation With Turbo-Elite
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease
Peripheral Vascular Disease
Lead sponsor: Spectranetics Corporation
Sponsor class: INDUSTRY
First posted: 2014-12-04
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective for this study is to prove the safety and effectiveness of the Spectranetics Turbo-Elite catheter in atherectomy treatment for infrainguinal arteries with catheter to vessel sizing of at least 50%.


Eligibility criteria: Inclusion Criteria:

* PAD with Rutherford Class 1-4
* Patient is able to walk unassisted or with non-motorized assistive devices.
* Documented PAD by ABI \<0.9 or previous intervention with reoccurrence of symptoms
* Documented stenosis by duplex ≥50%

Exclusion Criteria:

* Patient is pregnant or breast feeding.
* Evidence of Acute Limb Ischemia within 7 days prior to procedure.
* CVA \< 60 days prior to procedure.
* MI \< 60 days prior to procedure.
* Known contraindication to aspirin, antiplatelet/anti-coagulant therapies required for procedure/follow up.
* Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.
* Uncontrolled hypercoagulability or history of HIT or HITTS syndrome.
* Serum creatinine ≥ 2.5 mg/dL (unless dialysis-dependent) within one day prior to procedure.
* Patient is simultaneously participating in another investigational drug or device study that will interfere with the 30 day Safety Endpoint.
* Previously identified severe calcium in the vessel.

Primary outcomes:
measure: Primary Efficacy Endpoint - Mean Reduction in Percent Stenosis
timeFrame: Day 1
measure: Primary Safety Endpoint is Freedom From Major Adverse Event (MAE)
timeFrame: 30 day follow-up
Secondary outcomes:
measure: Final Procedure Residual Stenosis After All Therapy
timeFrame: Day 1
measure: Characterization of Adjunctive Therapy Use
timeFrame: Day 1
measure: Ankle-Brachial Index (ABI) Change From Baseline to 30 Days.
timeFrame: Baseline and 30 Days post-procedure
measure: Rutherford Class (RCC) Change
timeFrame: Baseline and 30 days of procedure
measure: Freedom From Target Lesion Revascularization (TLR) Through 180 Days.
timeFrame: Day 180 (6 Months)
Other outcomes:
Locations:
Study officials:
References: